Compass Therapeutics (NASDAQ:CMPX) Raised to “Hold” at Wall Street Zen

Compass Therapeutics (NASDAQ:CMPX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

CMPX has been the subject of a number of other research reports. Compass Point set a $10.00 price objective on Compass Therapeutics in a research report on Monday, October 6th. Raymond James Financial restated an “outperform” rating and set a $9.00 price objective on shares of Compass Therapeutics in a research report on Tuesday, January 6th. Lifesci Capital started coverage on Compass Therapeutics in a report on Monday, October 6th. They issued an “outperform” rating and a $10.00 price target on the stock. Canaccord Genuity Group assumed coverage on Compass Therapeutics in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $10.00 target price on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of Compass Therapeutics in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.23.

Compass Therapeutics Price Performance

CMPX opened at $6.40 on Friday. The stock has a 50-day moving average price of $5.46 and a 200-day moving average price of $4.28. The firm has a market cap of $1.14 billion, a PE ratio of -14.22 and a beta of 1.46. Compass Therapeutics has a 1 year low of $1.33 and a 1 year high of $6.49.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.06. As a group, sell-side analysts anticipate that Compass Therapeutics will post -0.36 EPS for the current year.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors have recently bought and sold shares of CMPX. Flagship Harbor Advisors LLC bought a new stake in Compass Therapeutics during the 4th quarter valued at $32,000. Russell Investments Group Ltd. grew its stake in shares of Compass Therapeutics by 3,933.7% during the third quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after acquiring an additional 7,592 shares during the last quarter. Apollon Wealth Management LLC acquired a new position in Compass Therapeutics during the 3rd quarter valued at approximately $35,000. CIBC Bancorp USA Inc. acquired a new position in shares of Compass Therapeutics in the 3rd quarter valued at $37,000. Finally, Creative Planning purchased a new position in shares of Compass Therapeutics in the second quarter worth about $30,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.